Thieler Law Corp advises investors with losses exceeding $100,000 of the September 12, 2016 lead plaintiff deadline in a class action lawsuit filed against Juno Therapeutics Inc (NASDAQ: JUNO) (“Juno” or “the Company”). The suit is pending in the U.S. District Court for the Western District of Washington and investors, who purchased Juno Therapeutics Inc securities between June 4, 2016 and July 7, 2016, have until September 12, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Juno Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that a patient died during a clinical trial for its product candidate in May 2016.

On July 7, 2016, Juno revealed that three patients had passed away during a clinical trial for the company’s chemotherapy drug, fludarabine.

Following this news, the Company's share price dropped over 30% to just $27.50 on July 8, 2016.

If you were negatively impacted by your investment in Juno Therapeutics Inc securities between June 4, 2016 and July 7, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185